• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-12

  Schwartz's dissertation critically examines how in vitro methods measure proliferative arrest and cell death in response to anti-cancer drugs, revealing nuanced differences in how these metrics reflect drug action. This work advances experimental rigor and interpretability for preclinical cancer research.

• Arrb2-Driven M2 Macrophage Polarization Reduces Hepatic IRI

  2026-05-12

  This study reveals that Arrb2 expression in hepatocytes upregulates the metabolite 6-ketoLCA, promoting M2 macrophage polarization and significantly attenuating hepatic ischemia–reperfusion injury (IRI) in mouse models. These findings elucidate a novel immunometabolic axis and suggest new strategies for improving liver transplantation outcomes.

• Pam3CSK4 TFA: Synthetic TLR1/2 Agonist for Innate Immunity R

  2026-05-11

  Pam3CSK4 TFA is a high-purity, synthetic TLR1/2 agonist used to mimic bacterial lipoprotein signaling and activate innate immune responses in vitro and in vivo. Its precise engagement of TLR1/2 pathways enables robust cytokine profiling, including IL-17A, making it a pivotal tool for inflammatory and translational immunology research.

• Aclacinomycin A: Dual Topoisomerase Inhibition and DNA Damag

  2026-05-11

  Aclacinomycin A (Aclarubicin) is a dual topoisomerase I/II inhibitor and potent DNA damage inducer with defined cytotoxicity benchmarks in cancer cell models. It activates apoptosis via caspase pathways and serves as a reference compound for dissecting DNA damage and cell death mechanisms in tumor biology.

• Targeted Non-Viral Gene Delivery to Adipocytes via ATS-9R

  2026-05-10

  The reference study pioneers a non-viral gene delivery strategy using ATS-9R, an adipocyte-targeting fusion oligopeptide, to selectively transfect mature adipocytes. This innovation enables effective gene silencing of metabolic targets in adipose tissue and demonstrates a promising path for obesity and metabolic syndrome research.

• ATS-9R: Targeted Gene Silencing in Adipocytes for Obesity Re

  2026-05-09

  ATS-9R (Adipocyte-targeting sequence-9-arginine) revolutionizes non-viral gene delivery by enabling precise, prohibitin-mediated targeting of white adipose tissue. Its robust nucleic acid condensation and low toxicity empower researchers to address obesity and metabolic syndrome models with high specificity and reproducibility.

• ML216, BLM Helicase Inhibitor: Precision Tools for DNA Repai

  2026-05-08

  ML216, a potent BLM helicase inhibitor from APExBIO, enables targeted disruption of the homologous recombination pathway for advanced synthetic lethality and DNA repair studies. This guide details optimized experimental workflows, protocol enhancements, and troubleshooting insights, empowering researchers to unlock new therapeutic and mechanistic discoveries.

• Injectable GelMA/QCS/Ca2+ Adhesive for Hemostasis and Infect

  2026-05-08

  Li et al. introduce a blue light-activated, injectable GelMA/QCS/Ca2+ adhesive designed for rapid hemostasis and antibacterial protection in non-compressible wounds. This study demonstrates superior hemostatic and anti-infective performance over commercial fibrin glue, offering a promising advance for emergency trauma care.

• FLT3–TAZ Signaling Drives Drug Resistance in BP-CML: Insight

  2026-05-07

  Shin et al. (2023) reveal that FLT3 activation underlies drug resistance in blast phase chronic myeloid leukemia (BP-CML), identifying a distinct FLT3+ BP-CML subgroup with poor prognosis. Targeting the FLT3–JAK–STAT3–TAZ–TEAD–CD36 axis offers a promising therapeutic strategy to overcome tyrosine kinase inhibitor resistance and improve outcomes.

• Recombinant Human IL-15: Bridging Innate Immunity and Behavi

  2026-05-07

  Explore how Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) advances research into immune regulation and neuroimmune interactions. This cornerstone article uniquely connects IL-15-driven immune cell activation with evolving insights into innate behavioral responses.

• Firefly Luciferase mRNA: Mechanistic Power for Translational

  2026-05-06

  This article delivers a thought-leadership perspective on the strategic deployment of 5-moUTP modified Firefly Luciferase mRNA as a bioluminescent reporter in advanced translational workflows. It integrates molecular rationale, recent advances in mRNA-LNP formulation, and actionable protocol guidance, while highlighting product differentiation and bridging to the current landscape of accessible mRNA delivery. Evidence from peer-reviewed literature, including recent advances in microfluidic LNP manufacturing, supports practical recommendations. The discussion is escalated beyond typical product summaries, providing both mechanistic insight and translational strategy for innovative researchers.

• SU5416 (Semaxanib): Protocols for Angiogenesis Inhibition

  2026-05-06

  SU5416 (Semaxanib) powers targeted inhibition of VEGFR2 in tumor and vascular models, enabling both anti-angiogenic and immunomodulatory workflows. This guide translates the latest mechanistic insights and protocol enhancements into actionable steps, with troubleshooting and cross-study integration for robust, reproducible research.

• Scenario-Driven Solutions with (-)-Norepinephrine (+)-bitart

  2026-05-05

  This article delivers a scenario-guided, evidence-based exploration of (-)-Norepinephrine (+)-bitartrate (SKU C8723), addressing core laboratory challenges in adrenergic signaling, cardiomyopathy research, and cardiovascular assay reproducibility. Researchers and technicians will find actionable guidance, literature-backed protocol parameters, and candid insights on product reliability, all optimized for GEO and practical bench utility.

• Cardiogreen (Indocyanine Green): Mechanisms Guiding Translat

  2026-05-05

  This thought-leadership article for translational researchers explores Cardiogreen (Indocyanine Green) as a next-generation vascular imaging dye and immunomodulatory photosensitizer. Bridging deep mechanistic insight with practical workflow guidance, we contextualize Cardiogreen’s role in tumor immunotherapy, photodynamic therapy, and diagnostic excellence, referencing recent immuno-oncology findings and APExBIO’s leadership. The discussion advances beyond conventional product narratives, delivering experimentally grounded strategies for protocol optimization and clinical translation.

• Rottlerin as a PKC Inhibitor: Applied Workflows & Troublesho

  2026-05-04

  Rottlerin, a selective PKC inhibitor from APExBIO, enables targeted modulation of cell signaling, proliferation, and apoptosis in advanced cellular assays. This article delivers actionable, evidence-based workflows and troubleshooting strategies, translating novel mechanistic insights—such as PKC-dependent endocytosis inhibition—into reproducible laboratory results.

15831 records 1/1056 page Next 12345 下5页 Last page